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abstract
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed
multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been
limited to immunomodulatory agents. Other options that complement the induction regimen with favorable
toxicity are needed.
PATIENTS AND METHODS The phase III, double-blind, placebo-controlled TOURMALINE-MM4 study randomly
assigned (3:2) patients with NDMM not undergoing ASCT who achieved better than or equal to partial response
after 6-12months of standard induction therapy to receive the oral proteasome inhibitor (PI) ixazomib or placebo
on days 1, 8, and 15 of 28-day cycles as maintenance for 24 months. The primary endpoint was PFS since time
of randomization.
RESULTS Patients were randomly assigned to receive ixazomib (n5 425) or placebo (n5 281). TOURMALINE-
MM4 met its primary endpoint with a 34.1% reduction in risk of progression or death with ixazomib versus
placebo (median PFS since randomization, 17.4 v 9.4 months; hazard ratio [HR], 0.659; 95% CI, 0.542 to
0.801; P , .001; median follow-up, 21.1 months). Ixazomib significantly benefitted patients who achieved
complete or very good partial response postinduction (median PFS, 25.6 v 12.9 months; HR, 0.586; P, .001).
With ixazomib versus placebo, 36.6% versus 23.2% of patients had grade $ 3 treatment-emergent adverse
events (TEAEs); 12.9% versus 8.0% discontinued treatment because of TEAEs. Common any-grade TEAEs
included nausea (26.8% v 8.0%), vomiting (24.2% v 4.3%), and diarrhea (23.2% v 12.3%). There was no
increase in new primary malignancies (5.2% v 6.2%); rates of on-study deaths were 2.6% versus 2.2%.
CONCLUSION Ixazomib maintenance prolongs PFS with no unexpected toxicity in patients with NDMM not
undergoing ASCT. To our knowledge, this is the first PI demonstrated in a randomized clinical trial to have single-
agent efficacy for maintenance and is the first oral PI option in this patient population.
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INTRODUCTION
Treatment for multiple myeloma (MM) is shifting in-
creasingly to maintenance and continuous therapy,
which improves outcomes versus fixed-duration
treatment followed by a remission period.1-3 Real-
world data suggest that, at relapse, approximately
one third of patients never receive second-line
treatment,4,5 highlighting the importance of maximiz-
ing progression-free survival (PFS) with initial therapy
and the need for tolerable, active treatment options for
long-term administration.6 Proteasome inhibitors (PIs),
immunomodulatory drugs, and monoclonal antibodies
are backbones of therapy for MM.7 However, there are
no approved maintenance or continuous therapy
options with PIs for initial therapy.8,9
Maintenance therapy prolongs PFS in the post-
transplantation and nontransplantation settings, and
overall survival (OS) when used post-transplantation.10-12
To date, only lenalidomide is approved as post-
transplantation maintenance therapy.13 There are
currently no agents specifically approved as main-
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for patients not undergoing autologous stem cell trans-
plantation (ASCT). These patients may receive continuous
treatment with one or more agents received as induction, such
as lenalidomide9,14,15 and/or daratumumab.8,16 In routine
clinical practice, treatment duration may be limited because of
toxicity and route of administration.6,17 More tolerable and
convenient options are required for this generally elderly
population, whomay not be eligible for transplantation because
of age or presence of comorbidities.18
The oral PI ixazomib is approved in combination with
lenalidomide-dexamethasone for the treatment of patients
with MM who have received one prior therapy.19 Ixazomib
as post-transplantation maintenance therapy prolongs PFS
versus placebo,20 with limited cumulative toxicity or impact
on quality of life (QoL).20,21 We report the efficacy and safety
of ixazomib as maintenance therapy in transplantation-
ineligible patients after standard-of-care induction therapy.
PATIENTS AND METHODS
Trial Design and Patients
In this randomized, double-blind, placebo-controlled,
phase III trial, patients were randomly assigned from April 23,
2015, through October 8, 2018, at 187 sites in 34 countries
(Data Supplement, online only). The trial was conducted in
accordance with the principles of the Declaration of
Helsinki, the International Conference on Harmonization
Good Clinical Practice guidelines, and appropriate regu-
latory requirements. Local independent ethics committees
or institutional review boards at each site approved the
protocol, which is available in the Data Supplement. All
patients provided written informed consent.
Adults with a confirmed diagnosis of symptomatic MM per
International Myeloma Working Group (IMWG) criteria22
who were ineligible for, or did not wish to receive, ASCT
and who achieved at least a partial response (PR) as their
best response after 6-12 months of any standard-of-care
induction therapy, were eligible. Patients required an
Eastern Cooperative Oncology Group performance status of
0 to 2 and documented initial disease state, initial therapy
and response, and cytogenetics and International Staging
System (ISS) disease stage assessments at diagnosis (Data
Supplement). Eligible patients were required to be ran-
domly assigned # 60 days after the last dose of induction
therapy.
Procedures
Using centralized randomization through an interactive
voice/web response system (Data Supplement), patients
were randomly assigned 3:2 to receive either oral ixazomib
3 mg or matching placebo on days 1, 8, and 15 of 28-day
cycles. The dose was increased to 4 mg from cycle 5 if
tolerated during cycles 1-4 (Data Supplement). Random-
ization was stratified by induction regimen (PI-containing v
non-PI therapy); preinduction ISS disease stage (I or II v III);
age at randomization (, 75 v$ 75 years); and response to
initial therapy at screening (complete response [CR] or very
good partial response [VGPR] v PR). Patients continued
treatment for approximately 24 months (if no treatment
delays, equivalent to 26 cycles, to the nearest complete
cycle) or until progressive disease (PD) or unacceptable
toxicity, whichever occurred first. Dose adjustments for
toxicities were permitted using protocol-specified dose-
modification guidelines.
Outcomes and Assessments
The primary endpoint was PFS, defined as time since
random assignment to first documentation of PD (per in-
dependent review committee [IRC] evaluation) or death as
a result of any cause. The key secondary endpoint was OS.
CONTEXT
Key Objective
Does the oral proteasome inhibitor ixazomib improve progression-free survival (PFS) in patients with newly diagnosed
multiple myeloma (NDMM) not undergoing autologous stem cell transplantation when used as maintenance therapy
after best response to any standard-of-care induction?
Knowledge Generated
Treatment with weekly ixazomib maintenance resulted in a statistically significant and clinically meaningful improvement in
PFS since randomization, with an 8-month increase in the median, and demonstrated PFS benefits in prespecified
patient subgroups, including a statistically significant benefit in patients who achieved complete or very good partial
responses to initial therapy, and benefits in patients with stage IIII disease, patients aged $ 75 years, and patients with
expanded high-risk cytogenetics. Ixazomib maintenance had a tolerable safety profile with no increase in health care use
or impact on patients’ self-reported quality of life as measured by European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 and EORTC QLQ-MY20 questionnaires.
Relevance
To our knowledge, ixazomib is the first induction-agnostic maintenance option investigated for transplantation-ineligible
patients with NDMM and represents a valuable treatment option in this setting.
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Secondary and exploratory endpoints are listed in the Data
Supplement.
Patient evaluations and follow-up are summarized in the
Data Supplement. Response was assessed on day 1 of
every treatment cycle and every 4 weeks during the PFS
follow-up period until PD. Response and PDwere evaluated
by an IRC blinded to both treatment assignment and in-
vestigator assessment of response; assessments were
based on central laboratory M-protein results, plus local
bone marrow and imaging data, using IMWG 2011 crite-
ria.23 Adverse events (AEs) were assessed throughout the
treatment period and through 30 days after the last dose of
the study drug and graded according to the National
Cancer Institute’s Common Terminology Criteria for Ad-
verse Events, version 4.03. For more details on assess-
ments, see the Data Supplement.
Statistical Analysis
The study used a closed sequential testing procedure for
the primary (PFS) and key secondary (OS) endpoints, in
this order. Two interim analyses (IAs), plus a final analysis,
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FIG 1. CONSORT diagram.
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primary and only analysis of PFS. See the Data Supplement
for detailed statistical analysis methodology. At this anal-
ysis, the study had 90% power to detect a hazard ratio (HR)
of 0.71 (two-sided log-rank test, two-sided alpha of .04) for
PFS in the intention-to-treat-population. Additionally, PFS
was tested in parallel in three prespecified subgroups per
stratification variables: patients with preinduction ISS stage
III disease, patients aged $ 75 years, and patients who
achieved CR or VGPR with initial therapy. Subgroup testing
for PFS was conducted using the remaining alpha (.01) and
the Hochberg procedure for multiplicity correction (Data
Supplement). The study was not powered for statistical
testing in other prespecified subgroups. The O’Brien-
Fleming alpha spending function (Lan-Demets method24)
was used to calculate the significance boundary for OS on
the basis of the observed number of deaths at each IA. All
other efficacy endpoints were tested at a two-sided alpha




A total of 706 patients with newly diagnosed MM (NDMM)
were enrolled (Fig 1), 425 in the ixazomib arm and 281 in
the placebo arm. Baseline patient demographics and
disease characteristics, including prior induction treat-
ment, were well balanced between groups (Table 1; Data
Supplement). Overall median age at study entry was
73 years, with 38.2% of patients aged$ 75 years; 35.3% of
patients had ISS stage III disease, 82.3% received a PI and
32.7% received an immunomodulatory drug as part of their
induction regimen, and 62.0% were in CR or VGPR at
study entry.
Efficacy
At data cutoff (August 12, 2019), with a median overall
follow-up for PFS of 21.1 months, there was a significant
34.1% reduction in risk of progression or death in the
ixazomib versus placebo group (HR, 0.659; 95% CI, 0.542
to 0.801; P , .001); median PFS since randomization was
17.4 months (95% CI, 14.8 to 20.3 months) versus
9.4 months (95% CI, 8.5 to 11.5 months; Fig 2A). When
landmarked to the date of induction therapy, median total
PFS time since start of induction was 26.3 versus
20.3 months in the ixazomib versus placebo group
(Table 2). In the prespecified subgroups, there was a sta-
tistically significant improvement in PFS since randomi-
zation with ixazomib versus placebo in patients who
achieved CR or VGPR with initial therapy (HR, 0.586;
95% CI, 0.449 to 0.765; P , .001). Clinical benefits were
observed in patients with ISS stage III disease (HR, 0.695;
95% CI, 0.499 to 0.967; P 5 .030) and patients







Median (range) 72 (42-89) 73 (52-90)
, 65 39 (9.2) 29 (10.3)
$ 65 and , 75 226 (53.2) 142 (50.5)
$ 75 160 (37.6) 110 (39.1)
Male sex 222 (52.2) 155 (55.2)
Racea
White 330 (77.6) 227 (80.8)
Asian 63 (14.8) 39 (13.9)
Black or African American 15 (3.5) 5 (1.8)
Type of myeloma at initial diagnosis
Immunoglobulin G 252 (59.3) 174 (61.9)
Immunoglobulin A 102 (24.0) 67 (23.8)
Light chain 62 (14.6) 36 (12.8)
Otherb 9 (2.1) 4 (1.4)
ISS disease stage at initial diagnosisc
I 112 (26.4) 66 (23.5)
II 165 (38.8) 114 (40.6)
III 148 (34.8) 101 (35.9)
ECOG PS at study entryd
0 213 (50.1) 147 (52.3)
1 193 (45.4) 120 (42.7)
2 18 (4.2) 14 (5.0)
Frailty statuse
Fit 172 (40.5) 112 (39.9)
Unfit 147 (34.6) 98 (34.9)
Frail 102 (24.0) 68 (24.2)
Creatinine clearance at study entry
(mL/min)f
, 30 8 (1.9) 3 (1.1)
30 to , 60 148 (34.8) 104 (37.0)
60 to , 90 184 (43.3) 108 (38.4)




74 (17.4) 48 (17.1)
Expanded high-risk
cytogenetic abnormalitiesh
150 (35.3) 91 (32.4)
Elevated lactate dehydrogenase
at study entry
57 (13.4) 38 (13.5)
Evidence of lytic bone disease
at study entry
203 (47.8) 141 (50.2)
(continued on following page)
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aged$ 75 years (HR, 0.738; 95% CI, 0.537 to 1.014; P5
.060; Table 2). PFS benefit in other patient subgroups is
summarized in Figure 2B.
Median time to progression was 17.8 versus 9.6 months
with ixazomib versus placebo, and response improvements
during maintenance were seen in 14.6% versus 8.2% of
patients (Table 2). PFS2 and OS data were not mature at
the time of this analysis. The study remains blinded; follow-
up for PFS2 and OS continues.
Treatment Exposure and Safety
The safety population included 426 and 276 patients in the
ixazomib and placebo groups, respectively (Fig 1). Treat-
ment exposure data are summarized in Table 3. At data
cutoff, patients had received a median of 13 (1 to 26) and
12 (1 to 26) treatment cycles in the ixazomib and placebo
groups, respectively, 16.0% and 10.1% of patients had
completed all protocol-specified cycles, and 19.5% and
15.3% were ongoing; 70.7% and 78.3% of patients dose-
escalated from the starting dose of 3 mg to 4 mg,
respectively.
In the ixazomib versus placebo group, 36.6% versus
23.2% of patients had grade $ 3 treatment-emergent
AEs (TEAEs), 22.1% versus 16.7% had serious TEAEs,
and 30.8% versus 5.1% had a dose reduction and
12.9% versus 8.0% discontinued because of TEAEs
(Table 3). TEAEs for which the incidence was$ 5% higher
with ixazomib versus placebo included nausea (26.8% v
8.0%), rash (25.6% v 10.5%), vomiting (24.2% v 4.3%),
diarrhea (23.2% v 12.3%), peripheral neuropathy (19.5% v
10.9%), and pyrexia (11.3% v 5.1%; Table 4). Most TEAEs
were grade 1 or 2 severity, with rates of grade $ 3 events
being # 3% for all individual TEAEs except pneumonia
(3.8% grade 3; n 5 16; ixazomib group). There was no
evidence of cumulative toxicity over the course of treat-
ment. Rates of cardiac arrhythmias, heart failure, hypo-
tension, liver impairment, and renal impairment were all low
and similar between groups (Table 4). Nine patients (2.1%)
in the ixazomib group had grade $ 3 events of renal im-
pairment (considered unrelated to the study drug in six);
three events resolved (two without drug interruption, one
after dose delay), three resulted in discontinuation, and the
one grade 5 event was considered unrelated to the study
drug. Of these patients, three had preexisting kidney dis-
ease, including the patient who died. The overall rate of
herpes zoster was 3.1% with ixazomib and 0.7% with
placebo; in patients receiving antiviral prophylaxis, rates
were 0.4% and 0%, respectively (Table 4). At a median
follow-up of 2 years, there was no difference in the rate of
new primary malignancies (Table 4).
Changes in mean Global Health Status/QoL score on the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire Core-30 are shown in
the Data Supplement. Scores were similar between groups








PI 351 (82.6) 230 (81.9)
Bortezomib 346 (81.4) 228 (81.1)
Immunomodulatory drug 137 (32.2) 94 (33.5)
Thalidomide 92 (21.6) 63 (22.4)
Lenalidomide 47 (11.1) 32 (11.4)
PI plus immunomodulatory
drug
66 (15.5) 44 (15.7)
Common regimens ($ 5% overall)
VMP 117 (27.5) 88 (31.3)
VCd 112 (26.4) 75 (26.7)
VTd 27 (6.4) 14 (5.0)
Rd 20 (4.7) 16 (5.7)
CTd 21 (4.9) 14 (5.0)
Response at study entryi
CR 96 (22.6) 62 (22.1)
VGPR 168 (39.5) 112 (39.9)
PR 161 (37.9) 107 (38.1)




9.5 (5.6-15.0) 9.4 (6.3-14.8)
NOTE. Data are No. (%) unless otherwise indicated. See the Data Supplement for
detailed baseline characteristics.
Abbreviations: CR, complete response; CTd, cyclophosphamide-thalidomide-
dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance
status; ISS, International Staging System; PI, proteasome inhibitor; PR, partial
response; Rd, lenalidomide-dexamethasone; VCd, bortezomib-cyclophosphamide-
dexamethasone; VGPR, very good partial response; VMP, bortezomib-
melphalan-prednisone; VTd, bortezomib-thalidomide-dexamethasone.
aAdditional categories reported for race are summarized in a footnote in the Data
Supplement.
bOther categories are summarized in a footnote in the Data Supplement.
cData shown are per patient-level data and not per data reported for
randomization stratification.
dData missing for one patient in the ixazomib arm.
ePatients’ frailty status was classified as fit, unfit, or frail on the basis of four
components: age, the Katz Index of Independence in Activities of Daily Living, the
Lawton Instrumental Activities of Daily Living Scale, and the Charlson Comorbidity
Index Scoring System. Frailty status was reported as missing in four patients (0.9%)
in the ixazomib arm and three patients (1.1%) in the placebo arm.
fData missing for one patient in the placebo arm.
gHigh-risk cytogenetic abnormalities were del(17p), t(4;14), and t(14;16). If all
three abnormalities were unknown, indeterminate, or missing, the patient was
called unclassifiable. There was no cutoff for defining the presence of del(17p). All
cytogenetic evaluations were performed locally according to local standards. See
the Data Supplement for additional details.
hExpanded high-risk cytogenetic abnormalities comprised the high-risk
cytogenetic abnormalities plus amplification of 1q21. See the Data Supplement for
additional details.
iPer investigator.
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at study entry and were maintained in both groups during
the protocol-defined treatment period.
Health care resource use (HRU) during treatment is
summarized in the Data Supplement. Ixazomib did not
result in additional HRU (hospitalizations, emergency room
stays, and outpatient visits).
DISCUSSION
Ixazomib maintenance after standard-of-care induction
treatment resulted in a statistically significant and clinically
meaningful25 34.1% reduction in the risk of progression or
death since the time of randomization compared with
placebo, with an 8-month increase in median PFS. Addi-
tionally, a statistically significant benefit was demonstrated
in patients who achieved CR or VGPR with initial therapy.
Outcomes since randomization favoring ixazomib were
seen in patients with ISS stage III disease and patients aged
$ 75 years. In the prespecified subgroups of patients with
no prior PI exposure and patients with prior immuno-
modulatory drug exposure, notable PFS benefits since
randomization (based on HRs) were seen with ixazomib
versus placebo. Although no PFS benefit was seen in the
small subgroup of patients with conventional high-risk cy-
togenetics [t(4;14), t(14;16), del(17p)], ixazomib showed
a PFS benefit in the larger subgroup with expanded high-risk
cytogenetics, incorporating patients with amp1q21 in line
with the current IMWG definition of high-risk cytogenetics.26
The benefits of ixazomib maintenance were realized in the
context of a well-tolerated safety profile and no adverse
impact on patients’ QoL or HRU, important considerations in
this generally elderly, transplantation-ineligible population;
similar and consistent findings have been reported from other
phase III studies of ixazomib-based therapy in different
treatment settings.21,27,28 TOURMALINE-MM4 (Clinical-
Trials.gov identifier: NCT02312258) findings also support the
significant PFS benefit seen with ixazomib versus placebo as
post-transplantation maintenance therapy in the TOURMA-
LINE-MM3 trial.20 Together, these studies demonstrate the
utility and prolonged activity of oral, once-weekly ixazomib
maintenance.
In the context of current therapy, the comparison versus
placebo is a limitation of TOURMALINE-MM4; however,
at the time of study design, there were no approved
or standard-of-care maintenance therapies in non-
transplantation NDMMand thus no clear comparator to use
instead of placebo. Furthermore, current standard-of-care
maintenance may vary among regions. Nevertheless, it is
well established that lenalidomide provides a significant
improvement in PFS after induction therapy in transplantation-
ineligible patients. In the Myeloma XI trial,10 lenalidomide
improved PFS since maintenance randomization versus ob-
servation.10 This study differs from TOURMALINE-MM4 in that
patients received maintenance after thalidomide- (48%) or
lenalidomide-containing (52%) induction10; that is, approxi-
mately half the patients received continuous lenalidomide
through induction and maintenance. Lenalidomide main-
tenance after lenalidomide-based induction also demon-
strated a PFS benefit, overall and since the start of
maintenance, versus placebo or no maintenance in the
MM-01512 and GIMEMA RV-MM-PI-20929 trials. In the
FIRST trial of transplantation-ineligible patients with NDMM,
continuous lenalidomide-dexamethasone since the start of
therapy demonstrated improved PFS versus fixed-duration
lenalidomide-dexamethasone, further highlighting the
benefit of maintaining long-term lenalidomide therapy.15
However, no significant OS benefits were reported in these
Placebo
HR (95% CI), 0.659 (0.542 to 0.801)
Log-rank test P < .001
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Time Since Random Assignment (months)
Median
PFS
39.2% (95% Cl, 33.6% to 44.7%)
24.1% (95% Cl, 18.5% to 30.2%)
FIG 2. Kaplan-Meier analysis of progression-free
survival (PFS) by independent review (A) in the
intention-to-treat population and (B) by pre-
specified patient subgroups. Stratified log-rank
tests and Cox models were used for interarm com-
parisons. Some subgroup data are not shown be-
cause of small patient numbers. (*) Data per
stratification variables. (†) Data per individual patient-
level clinical data after medical review. (‡) High-risk
cytogenetic abnormalities were del(17p), t(4;14), and
t(14;16). See the Data Supplement for additional
details. (¶) Expanded high-risk cytogenetic abnor-
malities comprised the high-risk cytogenetic abnor-
malities plus amplification of 1q21. See the Data
Supplement for additional details. CR, complete re-
sponse; HR, hazard ratio; IMiD, immunomodulatory
drug; ISS, International Staging System; PI, proteasome
inhibitor; PR, partial response; VGPR, very good partial
response.
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Subgroup
No. of Patients with PFS Events
(of total patients) Median PFS (months) HR (95% CI)
Ixazomib Placebo Ixazomib Placebo
All patients (n = 706) 228 of 425 198 of 281 17.4 9.4 0.659 (0.542 to 0.801)
Age at time of random assignment
< 75 years (n = 432)*









0.615 (0.480 to 0.788)
0.738 (0.537 to 1.014)
Prior PI exposure
Yes (n = 566)*









0.743 (0.597 to 0.924)
0.395 (0.251 to 0.622)
Preinduction ISS stage
I or II (n = 465)*









0.641 (0.503 to 0.816)
0.695 (0.499 to 0.967)
Response to initial therapy










0.586 (0.449 to 0.765)
0.756 (0.566 to 1.010)
Age
< 65 years (n = 68)†
≥ 65 years and < 75 years (n = 365)†













0.569 (0.297 to 1.090)
0.632 (0.480 to 0.833)
0.742 (0.539 to 1.021)
Sex
Male (n = 377)









0.700 (0.539 to 0.909)
0.620 (0.457 to 0.842)
Race
White (n = 557)
Asian (n = 102)













0.602 (0.483 to 0.751)
0.826 (0.458 to 1.491)
3.152 (0.356 to 27.875)
Region 
Asia-Pacific (n = 118)
Europe/Middle East/Africa (n = 505)













0.793 (0.471 to 1.337)
0.635 (0.503 to 0.801)
0.672 (0.337 to 1.343)
Frailty status
Fit (n = 284) 
Unfit (n = 245)













0.530 (0.387 to 0.727)
0.746 (0.526 to 1.058)
0.733 (0.481 to 1.117)
Prior IMiD exposure
Yes (n = 231)









0.498 (0.350 to 0.708)
0.734 (0.575 to 0.936)
ISS stage at initial diagnosis
I (n = 178)†
II (n = 279)†













0.741 (0.479 to 1.148)
0.555 (0.403 to 0.765)
0.712 (0.510 to 0.993)
Revised ISS stage at initial diagnosis
I (n = 86)
II (n = 347)
III (n = 92)

















0.531 (0.278 to 1.015)
0.667 (0.508 to 0.876)
0.966 (0.544 to 1.714)
0.644 (0.407 to 1.019)
Response at study entry
CR (n = 163)†
VGPR (n = 306)†













0.760 (0.434 to 1.332)
0.550 (0.410 to 0.737)
0.702 (0.491 to 1.004)
Cytogenetic risk‡
High risk (n = 122)
Standard risk (n = 465)













1.011 (0.631 to 1.621)
0.617 (0.484 to 0.787)
0.735 (0.401 to 1.347)
Cytogenetic risk¶
Expanded high risk (n = 241)
Standard risk (n = 256)













0.765 (0.550 to 1.063)
0.550 (0.388 to 0.780)
0.645 (0.424 to 0.983)
Reason for transplantation ineligibility
Age (n = 617)









0.651 (0.526 to 0.805)
0.783 (0.413 to 1.484)
1.000.125 0.25 0.50 2.00 4.00 8.00
Ixazomib Better Placebo Better
B
FIG 2. (Continued).
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four studies.10,12,15,29 Similarly, bortezomib-based mainte-
nance after bortezomib-based induction has contributed
to notable overall outcomes in transplantation-ineligible
patients in the GEM05MAS65,30 GIMEMA-MM-03-05,31
and UPFRONT studies32; however, the specific impact of
bortezomib-based maintenance or PI-based maintenance
more broadly has not been determined in a randomized,
placebo-controlled phase III trial.
Patients in TOURMALINE-MM4 received induction therapy
with a PI-containing and/or immunomodulatory drug–
containing regimen at the discretion of their treating phy-
sicians. No patients received prior ixazomib, although
82.6% received PI-based induction, resulting in continu-
ous PI-based therapy and a median total PFS of approxi-
mately 26 months. Evaluation of this overall median in the
context of other data in transplantation-ineligible patients
with NDMM is confounded by the immortal time bias aris-
ing from TOURMALINE-MM4 requiring patients to have
achieved greater than or equal to PR at enrollment after
6-12 months of standard-of-care induction therapy. Com-
parisons among studies are also confounded by various
patient- and disease-related factors, and should be avoided.
To our knowledge, TOURMALINE-MM4 is the first ran-
domized phase III trial to specifically investigate an
induction-agnostic maintenance approach—randomly
assigning patients to ixazomib versus placebo regardless of
the standard-of-care induction therapy received—in
transplantation-ineligible NDMM. The feasibility of main-
taining long-term PI-based therapy and convenience of oral
administration with ixazomib are valuable attributes for
treatment of the nontransplantation population, particularly
for elderly patients, and this unique approach may be of
value when considering tailoring treatment to specific
patients. Given the disease heterogeneity of MM, physi-
cians require options that enable them to amend and in-
dividualize first-line therapy. Prolongation of PFS with
ixazomib regardless of the standard-of-care induction
therapy is of potential value as an additional treatment
option, along with continuous therapy approaches15,16 with
lenalidomide12,29,33,34 or daratumumab8 after lenalidomide-
based or daratumumab-based induction.
An alternative approach to long-term PI-based therapy is
to use ixazomib in a continuous manner similar to that
used with lenalidomide12,29,33,34 or daratumumab.8 A
recent analysis of four phase II studies of ixazomib main-
tenance after ixazomib-based induction demonstrated
the feasibility and activity of this approach.35 The
phase III, placebo-controlled TOURMALINE-MM2 trial in
transplantation-ineligible patients with NDMM compared
ixazomib-lenalidomide-dexamethasone versus placebo-
lenalidomide-dexamethasone for 18 cycles, followed by
reduced-dose ixazomib-lenalidomide versus placebo-
lenalidomide from cycle 19 onward. At the time of publi-
cation, a PFS benefit with ixazomib-based therapy, with
a lengthy median, has been reported36 and the publication
of the full study results is awaited. Transplantation-ineligible
patients with NDMM are highly heterogeneous—one
treatment approach does not fit all. An induction-agnostic
maintenance or continuous therapy option may be of value
for optimizing therapy in individual patients.
TABLE 2. PFS in Patient Subgroups Prespecified for Testing for Statistical Significance, Time to Progression, and Response Improvements Seen With








Median PFS in prespecified subgroups, monthsa,b
Patients with a CR or VGPR with initial therapy (n 5 263 v n 5 175) 25.6 12.9 0.586 (0.449 to 0.765) , .001
Patients with preinduction ISS stage III disease (n 5 144 v n 5 97) 16.6 7.8 0.695 (0.499 to 0.967) .030
Patients aged $ 75 years (n 5 164 v n 5 110) 16.7 10.6 0.738 (0.537 to 1.014) .060
Median total PFS landmarked from start of induction, monthsb 26.3 20.3 0.650 (0.534 to 0.791) , .001
Median time to progression, monthsb 17.8 9.6 0.655 (0.537 to 0.799) , .001
Response improvements during maintenance
VGPR/PR patients with deepening response during treatment, No. (%) 62 (14.6) 23 (8.2) — .004c
VGPR patients converting to CR during study, No. (%) 41 (9.6) 16 (5.7) — —
PR patients converting to VGPR or better during study, No. (%) 21 (4.9) 7 (2.5) — —
Abbreviations: CR, complete response; ISS, International Staging System; PFS, progression-free survival; PR, partial response; VGPR, very good partial
response.
aSubgroup testing for PFS was conducted using an alpha of .01 and the Hochberg procedure for multiplicity correction. There was a significant difference
with ixazomib versus placebo in patients who had CR or VGPR with initial therapy, and there were benefits in patients with ISS stage III disease and in patients
aged $ 75 years, although these did not meet the significance test.
bKaplan-Meiermethodology was used to estimate time-to-event distributions, with stratified log-rank tests and Coxmodels used for interarm comparisons of
time-to-event endpoints.
cPer the Cochran-Mantel-Haenszel test stratified by response at study entry (PR v VGPR).
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TOURMALINE-MM4 demonstrated the tolerability of ixa-
zomib maintenance in this elderly population of
transplantation-ineligible patients; 70.7% of patients tol-
erated the 3-mg dose of ixazomib sufficiently well to es-
calate to 4 mg. Overall rates of TEAEs were similar between
groups, and TEAEs were mostly grade 1-2 severity. Rates of
serious TEAEs and discontinuations because of TEAEs
appeared slightly higher with ixazomib versus placebo,
whereas rates of on-study death and new primary malig-
nancies appeared similar. Common TEAEs that were more
frequent with ixazomib included GI toxicities, rash, and
peripheral neuropathy; however, rates of grade 3 events
were low in both groups. No new safety signals were seen,
reflecting the findings of TOURMALINE-MM3.20 In the
Myeloma XI trial of lenalidomide as maintenance post-
transplantation or postinduction, with a median duration
of therapy of eighteen 28-day cycles, 28% of patients who
had discontinued lenalidomide did so because of AEs.10
Furthermore, lenalidomide appeared to be associated with
higher rates of dose modifications (69%) and serious AEs
(45%)10 than seen in TOURMALINE-MM4 (dose re-
ductions, 30.8%; serious TEAEs, 22.1%) or TOURMA-
LINE-MM3 (19% and 27%, respectively),20 and an
elevated risk of new primary malignancies.10 The tolerable
safety profile of ixazomib maintenance in TOURMALINE-
MM4 was reflected in similar HRU data between arms and
in patient-reported QoL, which was maintained since study
entry in both arms and was generally similar throughout the
treatment period, indicating that active treatment with
ixazomib did not have a negative impact on patient-
reported QoL versus placebo in this double-blind trial.
In TOURMALINE-MM4, treatment duration was fixed at
2 years, based on the duration of bortezomib-based main-
tenance in prior phase III trials.31,37 At the time of trial design,
PI-based treat-to-progression approaches had not been
studied in a phase III trial, and, to date, the optimal duration
of PI-basedmaintenance remains to be determined. Longer-
term therapy may have resulted in improved outcomes in
some patients in TOURMALINE-MM4; however, because
median PFS was less than 24 months, the median would be
unlikely to be affected. With the favorable tolerability of
ixazomib, it was felt that this treatment duration could be
achieved with minimal discontinuations because of toxicity
and a reduced risk of developing resistant disease. Never-
theless, because median treatment duration was 13 cycles
and 16.0%of patients completed protocol-specified therapy,
treat-to-progression therapy is unlikely to have resulted in
prolonged treatment except in a few patients.
TABLE 3. Treatment Exposure and Overall Safety Profile in the Safety Population
Variable Ixazomib (n 5 426)a Placebo (n 5 276)a
Treatment cycles, median No. (range) 13 (1-26) 12 (1-26)
Dose escalated to 4 mg at cycle $ 5 301 (70.7) 216 (78.3)
Median duration of treatment at a dose/placebo equivalent of 4 mg, months (range) 6.0 (0-21) 7.8 (0-21)
Completed protocol-specified 26 cycles 68 (16.0) 28 (10.1)
Ongoing on treatmentb 83 (19.5) 43 (15.3)
Mean (SD) relative dose intensity, %c 90.4 (12.63) 96.6 (7.63)
Mean (SD) relative dose intensity in patients escalated to 4 mg at cycle 5, %c 93.7 (8.36) 98.6 (3.99)
Any TEAE 389 (91.3) 226 (81.9)
Any drug-related TEAE 284 (66.7) 111 (40.2)
Any grade $ 3 TEAE 156 (36.6) 64 (23.2)
Any drug-related grade $ 3 TEAE 76 (17.8) 12 (4.3)
Any serious TEAE 94 (22.1) 46 (16.7)
Any drug-related serious TEAE 22 (5.2) 3 (1.1)
TEAE resulting in discontinuation of the study drug 55 (12.9) 22 (8.0)
TEAE resulting in dose reduction of the study drug 131 (30.8) 14 (5.1)
Death during the treatment periodd 11 (2.6) 6 (2.2)
NOTE. Data are No. (%) unless otherwise indicated.
Abbreviation: SD, standard deviation; TEAE, treatment-emergent adverse event.
aTwo patients in the ixazomib group and two patients in the placebo group never received the study drug and were excluded from the safety
population. Three patients assigned to the placebo group erroneously received a single dose of ixazomib and were therefore analyzed as part of
the ixazomib group in the safety population.
bPercentages determined in the intention-to-treat-population (n 5 425; n 5 281) instead of the safety population.
cRelative dose intensity is defined as 100 3 (total amount of dose taken) / (total prescribed dose of treated cycles). Total prescribed dose of
treated cycles is calculated as: dose prescribed (3 mg, cycles 1-4, 3 mg or 4 mg, cycle 5 onward) 3 prescribed doses per cycle 3 number of
treated cycles (calculated separately for cycles 1-4 and cycle 5 onward in patients who escalated to 4 mg at cycle 5 onward).
dDeath during the treatment period was recorded through 30 days after receiving the last dose of the study drug or placebo.
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In conclusion, to our knowledge, ixazomib is the first
induction-agnostic maintenance option investigated for
transplantation-ineligible patients with NDMM. These re-
sults indicate that ixazomib is well tolerated and provides
a PFS benefit in this setting, thereby representing a valu-
able treatment option for patients. Subgroup analyses
suggest PFS benefit across this population, including in
elderly patients, those with preinduction ISS stage III disease,
and patients achieving CR or VGPR postinduction. Further-
more, ixazomib may provide a valuable maintenance option in
combination with other agents, such as immunomodulatory
drugs and monoclonal antibodies. TOURMALINE-MM4
continues in a double-blind fashion for long-term evaluation
of PFS2 and OS.
TABLE 4. Common TEAEs in the Safety Population ($ 10% in either group or rate difference of $ 5% between ixazomib and placebo groups)
Plus Other TEAEs of Clinical Interest
Adverse Event
Ixazomib Group (n 5 426) Placebo Group (n 5 276)
Any Grade Grade 3 Grade 4 Any Grade Grade 3 Grade 4
Common hematologic TEAEs of any cause
Thrombocytopeniaa 20 (4.7) 9 (2.1) 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0)
Neutropeniaa 10 (2.3) 8 (1.9) 1 (0.2) 9 (3.3) 4 (1.4) 0 (0.0)
Common nonhematologic TEAEs of any cause
GI disorders (MedDRA SOC) 222 (52.1) 22 (5.2) 0 (0.0) 93 (33.7) 7 (2.5) 0 (0.0)
Nausea 114 (26.8) 2 (0.5) 0 (0.0) 22 (8.0) 0 (0.0) 0 (0.0)
Vomiting 103 (24.2) 7 (1.6) 0 (0.0) 12 (4.3) 2 (0.7) 0 (0.0)
Diarrhea 99 (23.2) 8 (1.9) 0 (0.0) 34 (12.3) 2 (0.7) 0 (0.0)
Infections and infestations (MedDRA SOC)b 206 (48.4) 28 (6.6) 0 (0.0) 104 (37.7) 12 (4.3) 0 (0.0)
Upper respiratory tract infection 67 (15.7) 2 (0.5) 0 (0.0) 30 (10.9) 1 (0.4) 0 (0.0)
Rasha 109 (25.6) 12 (2.8) 0 (0.0) 29 (10.5) 0 (0.0) 0 (0.0)
Peripheral neuropathya 83 (19.5) 7 (1.6) 0 (0.0) 30 (10.9) 0 (0.0) 0 (0.0)
Back pain 61 (14.3) 1 (0.2) 0 (0.0) 31 (11.2) 1 (0.4) 0 (0.0)
Arthralgia 49 (11.5) 2 (0.5) 0 (0.0) 20 (7.2) 2 (0.7) 0 (0.0)
Pyrexia 48 (11.3) 1 (0.2) 0 (0.0) 14 (5.1) 0 (0.0) 1 (0.4)
Fatigue 46 (10.8) 6 (1.4) 0 (0.0) 28 (10.1) 1 (0.4) 0 (0.0)
Other TEAEs of clinical interest
Cardiac arrhythmiasa,c 18 (4.2) 6 (1.4) 0 (0.0) 13 (4.7) 2 (0.7) 0 (0.0)
Heart failurea,d 5 (1.2) 2 (0.5) 0 (0.0) 4 (1.4) 1 (0.4) 1 (0.4)
Hypotensiona 10 (2.3) 0 (0.0) 0 (0.0) 3 (1.1) 0 (0.0) 0 (0.0)
Liver impairmenta 19 (4.5) 6 (1.4) 0 (0.0) 7 (2.5) 3 (1.1) 0 (0.0)
Myocardial infarctiona,e 1 (0.2) 0 (0.0) 1 (0.2) 4 (1.4) 1 (0.4) 0 (0.0)
Renal impairmenta,f 16 (3.8) 4 (0.9) 4 (0.9) 5 (1.8) 0 (0.0) 0 (0.0)
Herpes zoster 13 (3.1) 1 (0.2) 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0)
In patients receiving antiviral prophylaxis 1/274 (0.4) 0 (0.0) 0 (0.0) 0/167 (0.0) 0 (0.0) 0 (0.0)
In patients not receiving prophylaxis 12/152 (7.9) 1/152 (0.7) 0 (0.0) 2/109 (1.8) 0 (0.0) 0 (0.0)
New primary malignant tumor 22 (5.2) — 17 (6.2) —
NOTE. Data are No. (%).
Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; SOC, system organ class; TEAEs, treatment-emergent adverse events.
aData were based on a standardized MedDRA query that incorporated pooled preferred terms or multiple preferred terms. Preferred terms
included within each standardized MedDRA query are summarized in the Data Supplement.
bSeven patients (1.6%) in the ixazomib group and one patient (0.4%) in the placebo group had grade 5 infections and infestations events,
including septic shock (n5 6), sepsis (n5 2), and viral pneumonia (n5 1) in the ixazomib group and septic shock (n5 1) in the placebo group.
cOne patient (0.2%) in the ixazomib group had a grade 5 event of cardiac arrest, and one (0.4%) in the placebo group had a grade 5 event of
sudden death.
dOne patient (0.2%) in the ixazomib group had grade 5 acute pulmonary edema.
eOne patient (0.4%) in the placebo group had grade 5 myocardial infarction.
fOne patient (0.2%) in the ixazomib group had grade 5 acute kidney injury.
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